Tanshinones Veterinary Grade API, designated model TAN-VET-98, is a refined multi-component diterpene quinone concentrate obtained from solvent extraction and chromatographic purification of Salvia miltiorrhiza root. The material is supplied as a red-brown to dark orange crystalline powder and is standardised to a total tanshinone content of 98.0% minimum on the dried basis by high-performance liquid chromatography, with the homologue profile composed primarily of tanshinone IIA, cryptotanshinone, tanshinone I, and dihydrotanshinone I. Two product variants are controlled: TAN-VET-98-O for oral solid dosage forms and in-feed premixes, and TAN-VET-98-I for non-aqueous solutions and parenteral formulations. The API is intended for further manufacture of tablets, hard capsules, granules, powders, premixes, and oil-based or co-solvent-based solutions for veterinary use. No harmonized veterinary monograph currently covers this exact multi-component tanshinone API; batch conformity therefore relies on supplier certificate of analysis limits aligned with USP <467> for residual solvents, USP <62> for specified microorganisms, and the HPLC method described in the Chinese Pharmacopoeia 2020 Salvia miltiorrhiza monograph. Published clinical efficacy data in target veterinary species are limited, and formulation development is based primarily on physicochemical, dissolution, and stability data rather than extrapolated dose-response claims.

Defining the TAN-VET-98 specification envelope

The release specification is built around total tanshinones by HPLC and the ratio of the four main lipophilic homologues. The homologue profile is stated as a range rather than a tight single value because seasonal and geographical variations in the botanical source remain measurable even after purification. The heavy metal panel follows feed-additive and veterinary drug expectations for oral administration; injectable grade adds endotoxin and sub-visible particulate controls. Table 1 lists the core release parameters and the corresponding test methods or standard chapters.

Because the API is intended for food-producing and companion animal dosage forms, residual solvent load is limited to the veterinary-relevant options of VICH GL18; the material is not released with residual acetone, ethyl acetate, ethanol, or methanol above compendial option limits. Injection-grade material is not interchangeable with oral-grade material without verification of endotoxin and particulate burden, because the oral grade is not guaranteed to meet the ≤0.5 EU/mg limit.

The major homologue tanshinone IIA is practically insoluble in water at 25 °C, with shake-flask solubility below 1 µg/mL; the API does not form a freely water-soluble salt by pH adjustment within the pharmaceutical range because the diterpene quinones are neutral lipophilic compounds with reported log P values above 5 for the major components. Solubility in absolute ethanol, acetone, dimethyl sulfoxide, soybean oil, and medium-chain triglycerides is substantially higher, which directs liquid dosage development toward co-solvent, oil, or mixed micellar systems. Differential scanning calorimetry of the multi-component API shows a broad melt transition, with the tanshinone IIA melting endotherm typically observed at 207–211 °C; the presence of cryptotanshinone and tanshinone I depresses and broadens the thermal event relative to single-entity tanshinone IIA. Alkaline pH and hydrogen peroxide accelerate degradation to quinone ring-opened products, while acidic and neutral conditions are less aggressive. Bulk storage under inert headspace at ≤25 °C and ≤60% RH is specified to limit photochemical and oxidative colour shift.

For tablets and capsules, the oral-grade API is typically micronized or classified to D90 ≤75 µm to support blend uniformity and dissolution. Direct compression is limited to low drug loading because the crystalline powder exhibits poor flow and high cohesion; at drug loads above roughly 10–20% w/w, roller compaction or wet granulation is required. High-shear granulation of TAN-VET-98 with povidone K30 or microcrystalline cellulose binders requires controlled water addition because localized overwetting creates pasty agglomerates; fluid-bed top-spray granulation at inlet air temperature 50–60 °C is generally preferred for granules and sachet powders. Tablet dissolution in 0.1 M HCl or water may show poor dispersion due to the hydrophobic surface; co-processing with sodium lauryl sulfate, poloxamer 188, or hydrophilic solid-dispersion carriers is used to produce measurable dissolution in apparatus II at 50–75 rpm. For hard capsules, the API is pre-blended with colloidal silicon dioxide at 0.5–1.0% w/w or filled as a liquid dispersion in medium-chain triglycerides to avoid segregation.

What restricts the use of TAN-VET-98 in aqueous injection and oral solution products?

The injection-grade variant TAN-VET-98-I is controlled for bacterial endotoxins at a typical acceptance limit of ≤0.5 EU/mg by USP <85> and for sub-visible particulate matter after dilution in the chosen solvent system. Nevertheless, the negligible aqueous solubility of the major tanshinone homologues prevents direct reconstitution in water for injection or isotonic saline. True solutions for parenteral use require co-solvents such as propylene glycol, polyethylene glycol 400, or ethanol, usually with surfactants such as polysorbate 80 or polyoxyl 35 castor oil. Typical co-solvent systems in published laboratory studies achieve tanshinone IIA concentrations in the 2–5 mg/mL range; however, published data for this specific veterinary API configuration are limited. Dilution with 0.9% NaCl injection at ratios of 1:5 to 1:50 should be assessed by dynamic light scattering or light obscuration per USP <788>; visible precipitation is a release failure. Terminal autoclaving at 121 °C for 15 min can produce measurable assay losses and darkening, so sterile filtration through 0.22 µm polyvinylidene fluoride membranes is preferred for non-aqueous solutions that have been prefiltered to remove insoluble homologue aggregates. For oral drench solutions, similar co-solvent systems are used, but regulatory solvent limits differ between food-producing species and companion animals.

When TAN-VET-98 replaces crude Salvia miltiorrhiza powder in premix and granule manufacture

Crude Salvia miltiorrhiza root powder typically carries 5–20% total tanshinones depending on plant origin, harvest time, and extraction process; this variability complicates fixed-dose premix manufacture because the active content must be re-assayed and the excipient load adjusted for every lot. The API replaces that variable input with a controlled total tanshinone assay and defined homologue ratio, reducing the need for feed-mill adjustment of active content. For in-feed premix, the oral-grade API is commonly first adsorbed onto calcium carbonate, corn starch, or rice hulls at 1–5% w/w active content and then diluted into complete feed at formulation-relevant levels. Charging into a horizontal ribbon blender at 60–80% vessel fill with post-addition mixing of 10–20 min is typical to achieve homogeneous distribution; blend uniformity is confirmed by sampling at the beginning, middle, and end of discharge. The dusty nature of micronized API requires vacuum transfer or laminar-flow handling, and cleaning validation for cross-contamination in feed mills should target tanshinone IIA as the marker. Published target-species pharmacokinetic data for these premixes are limited; release is therefore based on assay, blend uniformity, and stability rather than clinical efficacy extrapolation.

Compared with single-marker tanshinone IIA API, TAN-VET-98 retains cryptotanshinone and tanshinone I, which differ in metabolic susceptibility and membrane partitioning. Single-entity material offers a simpler impurity profile and is suitable when a veterinary product requires one defined active molecule, but it lacks the minor homologue fraction that may contribute to the botanical product's broader analytical fingerprint. Compared with water-soluble Salvia miltiorrhiza polyphenolic acids such as salvianolic acid B, tanshinones exhibit much lower aqueous solubility and higher log P, favouring lipid-based formulations and tissue-associated distribution, while polyphenolic acids are compatible with simple aqueous solutions. This polarity contrast determines dosage-form strategy: oral liquids and injectables from polyphenolic acids are comparatively straightforward, whereas tanshinone APIs require co-solvents, emulsions, solid dispersions, or adsorption onto carriers. Compared with unstandardised botanical extracts labelled loosely as tanshinone-rich, TAN-VET-98 provides a defined total content and heavy metal, residual solvent, and microbial limits suitable for veterinary release.

Storage, handling, and batch-to-batch variance under production-scale conditions

Batch-to-batch variance in the botanical source remains the largest source of non-clinical variability after purification, despite chromatographic fractionation. The specification range for homologue ratio is intentionally broad enough to accommodate this variance, but humidity and light exposure during dispensing can further shift the appearance and assay. Production-scale handling of the oral-grade micronized material in a single-unit blender with high-intensity intensifier bars has shown batch-to-batch flow differences when the particle-size distribution is not re-measured after milling; material with a tail above 150 µm tends to segregate in final premix bags. The API should not be combined with strong alkalizing agents or high-moisture feed matrices during long-term storage because alkaline microenvironments accelerate quinone degradation. Feed sterilisation by steam can increase moisture and cause clumping; if steam conditioning is unavoidable, the API premix should be added after cooling to below 40 °C. Residual solvent levels after chromatographic purification are low but must be confirmed by batch analysis; solvent interchange from ethanol to ethyl acetate can alter crystal habit and flow without changing HPLC assay.

Table 2 summarises the formulation-relevant differences among the multi-component API, crude root powder, and single-marker tanshinone IIA.

Published data for this specific configuration is limited in food-producing species; therefore, any formulation using TAN-VET-98 should be evaluated for blend uniformity, dissolution or dispersion behaviour, residual solvent clearance, and stability under target packaging before batch scale-up. Supplier change control should compare HPLC homologue ratios, particle-size distribution, and dissolution performance in the same solvent system, because plant-origin batches may differ even when total tanshinone assay remains above 98.0%.